$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
ATLANTA, Feb. 29, 2016 -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 36th Annual Cowen Healthcare Conference, to be held March 7-9, 2016 at the The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Wednesday, March 9, 2016 at 8:00 AM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences (NASDAQ:ALIM) (Alimera), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
For more information, please visit www.alimerasciences.com.
COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
